$7.40
Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Kyverna Therapeutics Sinks 13%: Here’s Why
Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
Overview
52-week range
$2.52
$14
44% of range
Avg surprise (last 3)
+10.0%
Avg reaction (last 2)
+2.0%
50% positive
Latest IV / EM
77%
EM ±17.6% · $8 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.66 | $-0.75 | +12.0% | +35.9% | -1.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.85 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.97 | $1.00 | +3.0% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-1.03 | $-1.21 | +14.9% | — | +5.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.80 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.67 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.12 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-23.27 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-20.86 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.67 | -$0.97 | +30.9% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-41M | — | $-39M | $-44M | $-47M | — | $-39M | $-33M |
| Net income | $-40M | — | $-37M | $-42M | $-45M | — | $-34M | $-29M |
| EPS (diluted) | $-0.66 | — | $-0.85 | $-0.97 | $-1.03 | — | $-0.80 | $-0.67 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $32M | $124M | $34M | $53M | $57M | $97M | $105M | $132M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $242M | $283M | $175M | $214M | $248M | $291M | $325M | $349M |
| Total assets | $257M | $294M | $187M | $227M | $261M | $305M | $339M | $363M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $61M | $62M | $35M | $42M | $37M | $38M | $36M | $30M |
| Total equity | $196M | $232M | $152M | $184M | $224M | $267M | $303M | $334M |